

Heart failure in patients with advanced chronic kidney disease

| | | |
|--|---|---|
| Submission date 03/03/2021 | Recruitment status Recruiting | <input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol |
| Registration date 16/03/2021 | Overall study status Ongoing | <input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results |
| Last Edited 19/02/2025 | Condition category Circulatory System | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol

Background and study aims

The kidneys filter the blood using very specialised blood vessels to remove waste and toxic substances, and returning vitamins, amino acids, glucose, hormones and other vital substances into the bloodstream. The kidneys also help to regulate the fluid volume of the blood. Kidney failure is when kidneys no longer function well enough to meet the needs of daily life. This can worsen to end-stage kidney disease (ESKD) which is when kidney function falls below 10% of normal function. Kidney failure can be treated by haemodialysis. Haemodialysis is a way of replacing some of the functions of your kidney, blood is filtered using an external machine and then returned to the body.

Patients with ESKD who are receiving haemodialysis are at increased risk for development of heart failure (HF). Heart failure (HF) is a frequent cause of death and disability in patients.

It is not easy to distinguish HF from water overload in patients with ESKD, and many patients on haemodialysis have exercise limitations unrelated to HF. Therefore the traditional definition of HF, which is based on exercise ability, is less useful in this population.

The study team have suggested two new definitions of heart failure. This study will test whether these newer definitions are able to better identify patients with a higher risk of heart failure.

Who can participate?

Clinically stable adult patients being treated by chronic hemodialysis in the collaborating haemodialysis units

What does the study involve?

Patients treated by haemodialysis in 6 collaborating haemodialysis units will be examined at the General University Hospital in Prague every 6-12 months until kidney transplantation. The examination at each session will involve basic history, clinical assessment of heart failure (HF) symptoms (through scans of the heart, analysis of the blood vessels, blood samples for markers of heart failure, body composition analysis), and completion of a questionnaire about heart failure.

What are the possible benefits and risks of participating?

A potential benefit is timely diagnosis of heart disease that would allow timely treatment. There are no associated risks anticipated.

Where is the study run from?

General University Hospital in Prague (Czech Republic)

When is the study starting and how long is it expected to run for?

From March 2019 to December 2025

Who is funding the study?

Ministry of Health Czech Republic and General University Hospital in Prague (Czech Republic)

Who is the main contact?

Dr Jan Malik, email: jan.malik@vfn.cz

Contact information

Type(s)

Scientific

Contact name

Prof Jan Malik

ORCID ID

<https://orcid.org/0000-0002-2386-3293>

Contact details

3rd Department of Internal Medicine

General University Hospital

U nemocnice 1

Prague

Czech Republic

128 08

+420604303144

jan.malik@vfn.cz

Type(s)

Public

Contact name

Dr Anna Valerianova

ORCID ID

<https://orcid.org/0000-0002-8864-0816>

Contact details

3rd Department of Internal Medicine

General University Hospital

U nemocnice 1

Prague

Czech Republic
128 08
+420 224 962 363
anna.valerianova@vfn.cz

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

Nil known

Study information

Scientific Title

CZEcking Heart failure in patients with advanced Chronic Kidney Disease (Czech HF-CKD)

Acronym

Czech HF-CKD

Study objectives

1. Newer heart failure (HF) definitions will better identify patients with more advanced structural heart changes, higher morbidity, and mortality. The newer definitions are as follows:
 - 1.1. Modified ADQI XI Workgroup definition (at least 2 criteria of structural heart disease with cut-off values used in the cardiological guidelines)
 - 1.2. Haemodynamic definition, defined as low effective cardiac index (<2.5 l/min/m²) at rest in patients with at least one of the following abnormalities:
 - 1.2.1. Left ventricular hypertrophy
 - 1.2.2. Left ventricular EF $<40\%$
 - 1.2.3. AVF flow volume >1500 ml/min, but in the absence of significant valvular/pericardial disease
 - 1.2.4. Diastolic dysfunction grade 2 or 3
 - 1.2.5. Moderate or severe left atrial dilatation (LAVi >40 ml/m²)
 - 1.2.6. Estimated pulmonary artery systolic pressure >40 mmHg
2. In patients with non-cardiac exercise limitation (orthopedical and neurological problems, myopathy, frailty, etc), the use of a combination of advanced structural heart changes and of elevated NTproBNP level could become an HF surrogate that would lead to a similar risk of endpoints as in the symptomatic HF subjects
3. Careful assessment of dry weight setting will enable us to estimate real-world HF prevalence by excluding simple water overload mimicking HF

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 23/05/2019, protocol amendment approved 23/05/20120, title amendment approved 18/02/2021, Institutional ethics committee of the General University Hospital in Prague (Na Bojišti 1, 128 08 Prague 2, Czech Republic; +420 224 964 131; eticka.komise@vfn.cz), ref: 789/19, protocol amendment ref: 30/20

Study design

Longitudinal prospective single-center observational cohort study with regular assessment of endpoints

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Hospital

Study type(s)

Diagnostic

Participant information sheet

No participant information sheet available

Health condition(s) or problem(s) studied

Heart failure in patients with advanced chronic kidney disease

Interventions

This is an observational study of a cohort of patients with advanced chronic kidney disease.

The study will collect basic history, clinical assessment of heart failure (HF) symptoms, and use of the "Prague CKD-HF questionnaire". The clinical assessment will include the following:

1. Blood samples (full blood count, albumin, total protein, NT-pro brain natriuretic peptide)
2. Expert echocardiography, detailed analysis of the volumes of heart cavities, quantification of valvular disease, diastolic dysfunction according to the recent guidelines, calcification extent, and cardiac output calculation (from the left ventricular outflow tract diameter and velocity-time interval)
3. Hemodialysis arteriovenous fistula flow volume (flow in the feeding brachial artery by duplex ultrasound)
4. Hydration status assessed clinically (effusions, edema) and estimation of central venous pressure by inferior vena cava diameter and collapsibility by bio-impedance
5. Body composition (bio-impedance by Body composition monitor, FMC) including total body water, overhydration, extra- and intracellular water, lean body mass, and fat body mass
6. Arterial stiffness (pulse wave velocity between carotid and femoral arteries using Sphygmocor)
7. Rhythm analysis (sinus rhythm vs. atrial fibrillation) using electrocardiography

In cases of water overload during the examination, dry weight adjustment will be recommended, and the patient invited for another examination within 6 weeks. Only examinations performed at the optimal hydration status will be included.

Participants will be followed up for assessment every 6 to 12 months until kidney transplantation, death, or the end of the study period.

Intervention Type

Other

Primary outcome measure

Current primary outcome measure as of 07/07/2021:

1. Incidence of cardiovascular death measured from patient notes between baseline and the end of the study
2. Worsening of heart failure (defined as worsening by 1 class of New York Heart Association Functional Classification, the incidence of hospitalization for de-compensation, an ejection fraction decrease by $\geq 10\%$, or new diagnosis of heart failure) measured using clinical assessment and patient notes every 6-12 months between baseline and the end of the study
3. Incidence of significant cardiovascular morbidity (acute coronary syndrome or stroke) measured from patient notes between baseline and the end of the study

Previous primary outcome measure:

1. Incidence of death measured from patient notes between baseline and the end of the study
2. Worsening of heart failure (defined as worsening by 1 class of New York Heart Association Functional Classification, the incidence of hospitalization for de-compensation, an ejection fraction decrease by $\geq 10\%$, or new diagnosis of heart failure) measured using clinical assessment and patient notes every 6-12 months between baseline and the end of the study
3. Incidence of significant cardiovascular morbidity (acute coronary syndrome or stroke) measured from patient notes between baseline and the end of the study
4. Coronary or valvular intervention (percutaneous or surgical) measured from patient notes between baseline and the end of the study

Secondary outcome measures

Current secondary outcome measures as of 07/07/2021:

1. Components of the primary endpoint measured from patient notes between baseline and the end of the study
2. Incidence of other cardiovascular morbidity (stroke, acute leg ischemia, pulmonary embolism, etc.) measured from patient notes between baseline and the end of the study
3. Need for dry weight decrease by $>3\%$ of body weight because of overhydration measured by body composition monitor every 6-12 months between baseline and the end of the study
4. Need of coronary or valvular intervention (percutaneous or surgical) measured from electrocardiography and echocardiography every 6-12 months between baseline and the end of the study
5. Incidence of pacemaker/defibrillator implantation measured from patient notes between baseline and the end of the study
6. Coronary or valvular intervention (percutaneous or surgical) measured from patient notes between baseline and the end of the study
7. Incidence of vascular access intervention measured from patient notes between baseline and the end of the study
8. Non-cardiac death measured from patients notes between baseline and the end of the study

Previous secondary outcome measures:

1. Components of the primary endpoint measured from patient notes between baseline and the end of the study
2. Incidence of other cardiovascular morbidity (stroke, acute leg ischemia, pulmonary embolism, etc.) measured from patient notes between baseline and the end of the study
3. Need for dry weight decrease by >3% of body weight because of overhydration measured by body composition monitor every 6-12 months between baseline and the end of the study
4. Need of coronary or valvular intervention (percutaneous or surgical) measured from electrocardiography and echocardiography every 6-12 months between baseline and the end of the study
5. Incidence of pacemaker/defibrillator implantation measured from patient notes between baseline and the end of the study
6. Incidence of vascular access intervention measured from patient notes between baseline and the end of the study

Overall study start date

10/03/2019

Completion date

31/12/2025

Eligibility

Key inclusion criteria

1. Treated by chronic hemodialysis in the collaborating haemodialysis units
2. Clinically stable
3. Willing to participate
4. ESKD treated by hemodialysis for at least 3 months
5. Aged >18 years

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

300

Total final enrolment

300

Key exclusion criteria

1. Planned kidney transplantation from a living donor within 3 months of the index visit
2. Life expectancy <6 months at the index (first) visit for any reason
3. No dementia

Date of first enrolment

10/06/2019

Date of final enrolment

31/12/2025

Locations**Countries of recruitment**

Czech Republic

Study participating centre

General University Hospital

U nemocnice 1

Prague

Czech Republic

12808

Sponsor information**Organisation**

General University Hospital in Prague

Sponsor details

U nemocnice 1

Prague

Czech Republic

128 08

+420 224 962 666

pavel.michalek@vfn.cz

Sponsor type

Hospital/treatment centre

Website

<http://www.vfn.cz/>

ROR

<https://ror.org/04yg23125>

Funder(s)

Funder type

Government

Funder Name

Ministerstvo Zdravotnictví České Republiky

Alternative Name(s)

Ministry of Health of the Czech Republic, MZCR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Czech Republic

Funder Name

Všeobecná Fakultní Nemocnice v Praze

Alternative Name(s)

General University Hospital in Prague, VFN

Funding Body Type

Government organisation

Funding Body Subtype

Other non-profit organizations

Location

Czech Republic

Results and Publications

Publication and dissemination plan

Planned study protocol publication in 2021. First analysis of echocardiographical findings planned publication in 2021-2022. Other publications in a high-impact peer-reviewed journals will follow.

Intention to publish date

01/03/2026

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| Results article | | 01/06/2023 | 19/02/2025 | Yes | No |